Novavax is a biotechnology company dedicated solely to the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases.

For more than fifteen years, our focus has been to innovate upon well-established technologies to create improved vaccines. Our experience with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS, provided hard-won lessons and significant progress illustrating that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.

Our recombinant technology platform creates three-dimensional nanostructures of the proteins critical to disease pathogenesis, demonstrated to produce a highly immunogenic response. They are combined with proprietary, immune-stimulating saponin-based adjuvants developed at Novavax AB. Our Matrix-M™ adjuvant has been shown to enhance immune responses and has been well tolerated in multiple clinical trials. Novavax’ vaccines are stored at standard refrigeration temperatures, enabling the use of existing vaccine supply and cold chain channels that make them practical for use in difficult-to-reach areas.

Chief Executive Officer
Stanley C. Erck

President, Research & Development
Gregory M. Glenn, MD

Locations
Novavax was founded in 1987 and is headquartered in Gaithersburg, Maryland. Today, the company has more than 1,400 employees globally:

- **Novavax, Inc. (Gaithersburg, MD, USA)**
  Research & Development, Manufacturing and Corporate
- **Novavax CZ (Bohumil, Czech Republic)**
  Antigen manufacturing
- **Novavax AB (Uppsala, Sweden)**
  Adjuvant manufacturing

Website
www.novavax.com

Social Media

Stock Exchange
NASDAQ (NVAX)

Mission
We never rest in our quest to protect the health of people everywhere.

Commitment to Equitable Access and Transparency
Novavax has advanced many efforts to ensure fair and equitable vaccine access to low- and middle-income countries worldwide.

Creating tomorrow’s vaccines today.